Evogliptin is a potent dipeptidyl peptidase-4 (DPP-4) inhibitor used as an antidiabetic agent to assist in the management of type 2 diabetes mellitus, while also undergoing clinical evaluation for other… Read more















Evogliptin is a potent dipeptidyl peptidase-4 (DPP-4) inhibitor used as an antidiabetic agent to assist in the management of type 2 diabetes mellitus, while also undergoing clinical evaluation for other conditions such as osteoporosis and renal impairment. To support rigorous pharmaceutical analysis, this category provides a comprehensive range of reference standards, including the active pharmaceutical ingredient, process-related impurities, diastereomers, and stable isotope labelled compounds. These materials are essential for laboratories performing precise impurity profiling and method validation, ensuring compliance with quality control standards throughout drug development. By utilizing these high-quality compounds, researchers can accurately identify, quantify, and characterize potential degradants or by-products, facilitating the development of robust analytical procedures for this therapeutic agent.